OctoPlus will provide both formulation development and clinical material manufacturing services to biotech and pharmaceutical companies across the globe.
The undisclosed contract value is expected to make a material contribution to OctoPlus’ 2012 revenues.
Financial details on the compound and activities have not been disclosed.
OctoPlus is focused on the development and manufacture of improved injectable pharmaceuticals, long-acting, controlled release versions of known protein therapeutics, peptides and small molecules.
Â